Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
| ▸ | FABP1 | P07148 | 1/20 | 0.50 |
| ▸ | FABP6 | P51161 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265804 | 0.82 | CYP1A2 (0.70) | CYP2C19CYP1A2NPC1RAB9ATP53 | |
| SCHEMBL21677914 | 0.81 | CYP2C19 (0.58) | CYP2C19CYP1A2NPC1RAB9ATP53 | |
| SCHEMBL327850 | 0.79 | CYP2C19 (0.65) | CYP2C19CYP1A2NPC1RAB9ATP53 | |
| SCHEMBL31015708 | 0.79 | CYP2C19 (0.65) | CYP2C19CYP1A2NPC1RAB9ATP53 | |
| SCHEMBL1837886 | 0.78 | CYP1A2 (0.66) | CYP2C19CYP1A2NPC1RAB9ATP53 | |
| SCHEMBL10861718 | 0.78 | CYP1A2 (0.66) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL27761585 | 0.77 | CYP2C19 (0.62) | CYP2C19CYP1A2NPC1RAB9ATP53 | |
| Hydrochloric Acid SCHEMBL17871621 | 0.77 | CYP2C19 (0.62) | CYP2C19CYP1A2NPC1RAB9ATP53 | |
| SCHEMBL1344396 | 0.77 | CYP2C19 (0.62) | CYP2C19CYP1A2NPC1RAB9ATP53 | |
| SCHEMBL19957596 | 0.76 | SMN1; SMN2 (0.50) | CYP2C19CYP1A2NPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675809-B1 | USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3675809-B1 | USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2023-09-27 | — | — | EP | disclosed |
| CN-111343963-B | Use of physiologically cooling active ingredients and compositions comprising such active ingredients | 巴斯夫欧洲公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11434220-B2 | Use of physiological cooling active ingredients, and compositions comprising such active ingredients | BASF SE (DE) | 2022-09-06 | — | — | US | disclosed |
| US-20200190052-A1 | USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20200190052-A1 | USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2020-06-18 | — | — | US | disclosed |
| WO-2019043164-A1 | USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2019-03-07 | — | — | WO | disclosed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434220-B2 | Use of physiological cooling active ingredients, and compositions comprising such active ingredients | TRPM8, TRPM7, TRPM5 | CYP2C19 2096/4885CYP1A2 2141/4885NPC1 708/4885 |
| US-20200190052-A1 | USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS | TRPM8, TRPM7, TRPM5 | CYP2C19 2096/4885CYP1A2 2141/4885NPC1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.